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This study compared flow-mediated dilatation (FMD), peripheral artery tonometry (PAT), and serum nitric oxide (NO) measures
of endothelial function in patients with peripheral artery disease (PAD) against age/gendermatched controls. 25 patients (mean age:
72.4 years, M : F 18 : 7) with established PAD and an age/gender matched group of 25 healthy controls (mean age: 72.4 years, M : F
18 : 7) were studied. Endothelial function was measured using the % FMD, reactive hyperemia index (RHI) using PAT and serum
NO (𝜇mol). Difference for eachmethod between PAD and control patients and correlation between themethods were investigated.
FMD and RHI were lower in patients with PAD (median FMD for PAD = 2.16% versus control = 3.77%, 𝑝 = 0.034 and median
RHI in PAD = 1.64 versus control = 1.92, 𝑝 = 0.005). NO levels were not significantly different between the groups (PADmedian =
7.70 𝜇mol, control median = 13.05 𝜇mol, 𝑝 = 0.662). These results were obtained in elderly patients and cannot be extrapolated to
younger individuals. FMD and PAT both demonstrated a lower hyperaemic response in patients with PAD; however, FMD results
in PAD patients were unequivocally reduced whereas half the PAD patients had RHI values above the established threshold for
endothelial dysfunction. This suggests that FMD is a more appropriate method for the measurement of NO-mediated endothelial
function.
1. Introduction
The vascular endothelium, the functional lining of blood ves-
sels, plays a critical role in vascular homeostasis.Through the
local production of nitric oxide (NO) the normal endothe-
lium has the capacity to regulate vascular tone, coagulation,
inflammatory cell adhesion, and vascular smooth muscle
cell proliferation [1, 2]. Whereas normal endothelial function
is thought to be atheroprotective, endothelial dysfunction
occurs early in the development of atherosclerotic lesions and
is characterised by a prothrombotic phenotype and reduced
bioavailability of nitric oxide [1, 3]. Indeed endothelial dys-
function is increased in atherosclerotic conditions such as
coronary heart and peripheral artery disease (PAD) and is an
independent predictor of future cardiovascular events [4, 5].
Given its central role in the pathogenesis of athe-
rosclerosis, endothelial dysfunction is of great interest to
investigators studying interventions that may improve
endothelial function in the hope that improvements may
modify disease progression and future cardiovascular risk.
There is some evidence that endothelial dysfunction in
patients with PAD [4, 6] can be improved; however, there
are a number of different methods available to measure
endothelial function and it is not clear which is the most
appropriate for patients with PAD.
In a majority of clinical studies endothelial function is
typically quantified by measuring flow-mediated dilatation
(FMD), which is defined as vasodilation of an artery in
response to an increase in luminal blood flow and thus
laminar shear-stress [7]. This is routinely achieved by induc-
ing hyperaemia following a brief ischaemic stimulus and
vasodilatation occurs primarily through the effects of NO [8].
Measurement of FMD, however, is operator dependent and
requires considerable skill and experience. Peripheral artery
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Table 1: Characteristics of the sample groups.
Controls (𝑛 = 25) PAD (𝑛 = 25)
Mean age (years) (SD), range 72.40 (7.21), 59–85 72.36 (8.91), 58–90 𝑝 = 0.986
Gender: male : female 7 : 18 7 : 18
Mean BMI (SD), range 28.7 (5.19), 19.9–43.7 28.3 (5.18), 22.3–43.6 𝑝 = 0.803
PAD: peripheral arterial disease, SD: standard deviation, and BMI: body mass index.
tonometry [9] (PAT) is a more recently developed alternative
method of endothelial functionmeasurement. PATmeasures
the ratio of baseline digital pulse wave amplitude at rest and
after 5 minutes of brachial artery occlusion [10].This method
requires less training and experience and is largely automated
making it an attractive alternative to FMD. While FMD
and PAT both measure hyperaemic response, a surrogate for
NO bioavailability, they are measured in different parts of
the circulation (conduit and resistance vessels, resp.), with
varying dependence on NO [11]. Furthermore, in our unit,
we have observed a poor correlation between FMD and PAT
[12].
Serum biomarkers have also been used to assess endothe-
lial dysfunction; however, direct measurement of serum NO
is problematic due to its highly reactive nature and short half-
life. By using ELISA techniques to measure NO metabolites,
nitrate, and nitrite, one can indirectly measure NO activity
via serum or urine samples [13]; however, it remains unclear
how this relates to other measures such as FMD and PAT.
While the above methods have previously been used
to assess endothelial function in a number of different
populations, a comparison of these three methods has not
been performed in a group with PAD. The aim of this study
was to investigate whether there was a difference between the
PAD and control groups for each of the three measurement
methods and whether there is a correlation between the
methods.
2. Methods
2.1. Participant Selection. Data was collected from partici-
pants enrolled in two studies in which FMD, PAT, and venous
blood collection were performed as part of the investigation
of specific interventions.
The first study was investigating the effects on endothelial
function of moderate dose fish oil on healthy participants
with no evidence of PAD [14]. The second study was
investigating the effects of two different exercise regimes
on participants with intermittent claudication [15]. Baseline
FMD and PAT tests and venous blood as part of these studies
were used.
The sample populations consisted of 25 participants with
symptomatic PAD (claudication, Rutherford classification 1–
3) in the exercise intervention study and 25 controls, age
and gender matched to the PAD group, from the fish oil
intervention study. The age, gender, and BMI data for each
group are presented in Table 1. The control group and PAD
group were well matched with no significant difference for
age, gender, or BMI between the groups. No participants were
on nitrate-based medications. All patients with PAD were on
statins (which were withheld for a 24-hour period prior to
testing) while none were in the control group.
This analysis was limited to the baseline tests because of
the nonindependent nature of follow-up measurements and
the risk of confounding variables due to potential differing
effects of the interventions on each test.
This study was approved by the Southern Adelaide
Clinical Human Research Ethics Committee. All participants
provided written informed consent for the measurement of
FMD, PAT, and serum NO levels prior to commencement of
data collection.
2.2. Peripheral Arterial Tonometry. Participants were in-
structed to fast for eight hours, refrain from caffeine, alcohol,
and tobacco, and avoid exercise for eight hours prior to
testing.
PAT tests were performed using an EndoPAT device
(Itamar Medical Ltd., Caesarea, Israel), following the man-
ufacturer’s guidelines, in a quiet, dimmed, and temperature
controlled room as previously described [12] with upper
arm occlusion at 250mmHg. The hyperaemic response was
analysed using the device’s proprietary software and the
reactive hyperemia index (RHI) was calculated from pre- and
post-occlusion measurements by the device software using
the method previously described by McCrea et al. [10].
2.3. Brachial Artery Ultrasound Flow-Mediated Dilatation.
Fifteen minutes after the completion of the PAT testing,
FMD was performed by a single experienced operator with
the participant supine and the right arm in a supportive
cradle with the transducer held in a stereotactic stand,
following accepted guidelines [16] using forearm occlusion as
previously described [12].Thirty seconds of baseline imaging
and three minutes of post occlusion imaging were recorded
to obtain baseline and the maximal hyperaemic response
measurements. The brachial artery diameter was measured,
during diastole, using automated edge detection software
(Brachial Artery Analyser, MIA-LLC, Coralville, USA). The
% FMD was calculated using the following equation:
FMD (%)
= [
(maximum diameter − baseline diameter)
baseline diameter
]
× 100.
(1)
2.4. Serum NO. Peripheral venous blood was drawn into
4mL serum separator evacuated tubes, allowed to clot for
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Table 2: RHI, FMD, and NO results for age and gender matched controls and patients with PAD.
Controls (𝑛 = 25) PAD (𝑛 = 25)
RHI median, IQR 1.92, 1.84–2.24 1.64, 1.34–2.01 𝑝 = 0.005
FMD%median, IQR 3.77, 1.87–6.15 2.16, 0.59–4.17 𝑝 = 0.034
NO (𝜇mol) median, IQR 13.05, 5.58–19.06 7.70, 6.17–15.07 𝑝 = 0.662
PAD: peripheral arterial disease, IQR: interquartile range, FMD: flow-mediated dilatation, RHI: reactive hyperaemia index, and NO: nitric oxide.
10min, and then immediately centrifuged at 3,000 g for 7
minutes at 20∘C. Serum was stored at −80 degrees Celsius
and thawed for later total NO assay. Due to the instability
and short half-life ofNO,measurementwas performed on the
NO metabolites, nitrite (NO
2
−), and nitrate (NO
3
−). Nitrate
was converted to nitrite using an enzyme nitrate reductase
and the nitrite levels were then measured with a coloured
azo dye product of the Griess reaction using visible light at
540 nm (Total Nitric Oxide Assay Kit; Pierce Biotechnology,
Rockford, IL) [17]. The nitrite levels detected represented the
total NOmetabolites present in each sample and the kit is able
to recover 98% of nitrate in serum. Results were expressed in
𝜇mol with a detection limit of 0.35 𝜇mol and a CV of 5.3%.
2.5. Testing of Reproducibility. Test-retest reproducibility test-
ing was performed for both FMD and PAT as described
previously [12]. Brachial artery diameter intraclass coefficient
(ICC) = 0.989 (𝑝 < 0.001) and coefficient of variation (CV)
= 1.52%, FMD ICC = 0.884 (𝑝 = 0.002) and CV = 15.0%, and
RHI ICC= 0.298 (𝑝 = 0.304) and CV= 19.3%. Intra-assay CV
for serum total NO assays was 9.8%.
2.6. Statistical Analyses. Data were analysed using the SPSS
for Windows statistical package version 20 (SPSS Inc.,
Chicago, IL, USA).
The mean, standard deviation (SD) and range were
reported for age and body mass index (BMI) and Student’s
𝑡-test was used to test for difference between controls and
patients with PAD. Due to the nonparametric nature of
the FMD, RHI, and serum NO results, data median and
interquartile range (IQR) were reported and Mann-Whitney
𝑈 tests were performed to assess for differences in results
between the controls and those with PAD.
Correlation between FMD, RHI from PAT, and NO was
assessed using Spearman correlation coefficient.
Test-retest reproducibility was assessed using the intra-
class correlation coefficient (ICC) and coefficient of variation
(CV) for the first and second measurements in the group of
healthy volunteers.
All tests were two-tailed and the level of statistical
significance was set at 𝑝 < 0.05.
3. Results and Discussion
3.1. Results. The results for each test of endothelial function
are presented in Table 2. The distribution of results for each
method in controls and patients with PAD are displayed in
Figures 1, 2, and 3.
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Figure 1: Plot of distribution of RHI values for age and gender
matched controls and patients with PAD, 𝑝 = 0.005.
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Figure 2: Plot of distribution of FMD % values for age and gender
matched controls and patients with PAD, 𝑝 = 0.034.
FMD and RHI were significantly lower in PAD patients
compared to controls (FMD 𝑝 = 0.034; PAT 𝑝 = 0.005).
There was no significant difference in NO levels between the
two groups (𝑝 = 0.662).
No correlation was seen between the three tests of
endothelial function in the participants with PAD (RHI
versus FMD: 𝑟 = 0.182, 𝑝 = 0.205, RHI versus NO: 𝑟 = 0.034,
𝑝 = 0.815, FMD versus NO: 𝑟 = 0.07, 𝑝 = 0.627).
3.2. Discussion. To the best of our knowledge this is the
first study to investigate the relationship of FMD, PAT, and
serum NO metabolites in a sample of patients with PAD
and to compare these three measures of endothelial function
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Figure 3: Plot of distribution of NO concentrations for age and
gender matched controls and patients with PAD, 𝑝 = 0.662.
between patientswith PADand a group controlled for age and
gender. Both FMD and PATmeasurements were significantly
lower in this sample of PAD patients compared to age and
gender matched controls; however, no significant difference
was seen in results for serum NOmetabolites.
The FMD results from the current study were markedly
lower than that of the two previous studies of FMD in PAD
patients and controls (5.40%–6.45% for PAD and 9.79%–
12.80% for controls [3, 14] compared to 2.16% for PAD and
3.77% for controls in the current study). In part this may
be due to differences in reporting of the data but it is also
likely to be due to variations in technique as the two earlier
studies used upper arm occlusion for FMD. This is known
to be less dependent on NO-mediated dilatation and to
produce a higher percentage dilatation [18] than the more
widely accepted forearm method used in the current study.
The current study is the first to demonstrate lower RHI in a
sample of PAD patients compared to age and gendermatched
controls, indicating that the hyperaemic response is blunted
in this patient group. However, the RHI measured in many
of the PAD patients was high in relation to the previously
reported threshold RHI value for endothelial dysfunction of
1.67 [9]. The median RHI of this group was 1.64 and based
on the above threshold nearly half the PAD patients would
be classified as having normal endothelial function. This is
very surprising since this was a group with demonstrated
symptomatic atherosclerotic disease and markedly lowered
FMD values. It is known that NO-mediated vasodilatation
is responsible for less than half the hyperemic response
measured by PAT [19]. The relatively high RHIs measured by
PAT in the PAD patients may relate to retention of the non-
NO-mediated mechanisms that contribute to the hyperemic
response as measured by PAT. This study highlights the need
for studies to establish the underlying mechanisms of the
hyperemic response in patients with PAD. These findings
raise concerns that PAT may not be the most appropriate
method for assessing NO-mediated endothelial function.
The lack of correlation between FMD and PAT in the
current study is consistent with previous studies that use
forearm occlusion for the FMD testing [12].This is consistent
with the evidence that these methods measure different
aspects of the hyperemic response [18, 19].
The lower endothelial function found in PAD patients
implies that there is the potential for improvement in
endothelial function and this has been demonstrated in
studies using FMDbefore and after surgical and endovascular
interventions [20, 21]. The low FMD levels in the healthy
controls (consistent with the known reduction in endothelial
function with age [22]) suggest that the capacity for improve-
ment in PAD patients may be limited and it is unclear if
suchmild improvements confer any long term health benefits
related to reduced cardiovascular risk or delayed disease
progression.
The lack of difference in serum measurement of NO
metabolites may be due to the wide distribution in the
NO results. This test is known to be highly sensitive to
environmental factors [13]. Handling and analysis of samples
were standardized in an effort to minimize these effects.
In addition serum NO levels are affected by degradation
associated with oxidative stress, which is expected to be
higher in elderly patient with PAD. The high variability in
results suggests that this may not be a robust test and may
be of limited use in clinical studies.
A further limitation of this study is the variability of test
results with all three methods. High variability of the NO
results was found evenwith strict standardization of handling
and analysis. FMD was found to have a better ICC and a
CV than PAT. This is consistent with the only other report
comparing reproducibility of the two methods [23]. It is well
recognized that both of thesemethods have considerable test-
retest variability. This appears to be intrinsic to the methods
and relates to physiological variations rather than technical
factors [24].
The use of vasoactive drugs is a potential source of
variability; however, none of the participants were taking
nitrate-based pharmacotherapy. All the PADpatients were on
statinswhich are known to improve endothelial function [25].
As this study has demonstrated a reduction in endothelial
function in these patients, the use of statins may, at worst,
have decreased the observed reduction without affecting the
overall conclusions.
A limitation of this study is that the endothelium-
independent response of subjects was not assessed. This is
feasible with FMD and allows assessment of both endothe-
lial and nonendothelial mechanisms that may affect the
hyperemic response. It is not feasible with PAT [26] and
so comparison between these techniques could only be
undertaken for endothelial-dependent vasodilatation.
Another potential limitation is that the participants were
not recruited specifically for this study but were already
enrolled in existing intervention studies. As data were
restricted to preintervention baseline testing this should not
have an influence on the reported results.
The small sample size of this study is also a limitation.
However, even with this limitation there was a significant
difference in FMD and RHI between PAD patients and
controls.
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4. Conclusion
This study has found that assessment of the hyperemic
response by both FMDandPAT testing shows lower endothe-
lial function in PAD patients when compared to age and
gender matched controls. Serum NO results show a high
degree of variation and did not demonstrate a significant
difference between the groups. The difference in endothelial
function between PAD patients and age-gender matched
controls suggest an opportunity to improve endothelial
function in PAD patients, though this may be limited by
age dependent deterioration. Investigation is required into
whether an improvement in endothelial function results in
longer term health benefits in these patients.
An important limitation of these results that needs to be
considered with this study is that the results were obtained
in elderly patients with PAD and cannot be extrapolated to
younger or less diseased individuals.
Both FMD and PAT are valid methods for assessing
endothelial function in a research setting but the documented
intertest variationmakes them unsuitable for use in assessing
individual patients in a clinical setting. If NO-mediated
endothelial function is the phenomena of interest under
investigation FMD would appear to be the more appropriate
test as it is more purely NO-mediated in nature, demonstrates
a more clear-cut reduction in patients with PAD, and has
better reproducibility.
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